hVIVO (LON:HVO) Given Buy Rating at Shore Capital Group

hVIVO (LON:HVO)‘s stock had its “buy” rating reissued by analysts at Shore Capital Group in a research note issued to investors on Wednesday,London Stock Exchange reports.

Separately, Stifel Nicolaus restated a “hold” rating and issued a GBX 10 price objective on shares of hVIVO in a report on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, hVIVO has an average rating of “Moderate Buy” and an average price target of GBX 15.

hVIVO Stock Up 2.2%

Shares of HVO traded up GBX 0.20 during midday trading on Wednesday, reaching GBX 9.40. The stock had a trading volume of 15,131,094 shares, compared to its average volume of 3,525,599. hVIVO has a 1-year low of GBX 4.31 and a 1-year high of GBX 19.50. The company’s fifty day simple moving average is GBX 7.95 and its two-hundred day simple moving average is GBX 6.85. The company has a market cap of £64.71 million, a price-to-earnings ratio of 12.21 and a beta of 1.67. The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16.

hVIVO (LON:HVO) last announced its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) earnings per share for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. The firm had revenue of GBX 4,677 million during the quarter. Equities research analysts expect that hVIVO will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.